TITLE

Are Diabetes Prevention Treatments Truly Disease Modifying?

AUTHOR(S)
Kuritzky, Louis
PUB. DATE
August 2011
SOURCE
Neurology Alert;Aug2011 Clinical Brief, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses research published by the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Trial Investigators in a 2011 issue of "Diabetes Care" which analyzed glycemic control 2-3 months after cessation of ramipril or rosiglitazone.
ACCESSION #
64442587

 

Related Articles

  • Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Hanley, Anthony J.; Zinman, Bernard; Sheridan, Patrick; Yusuf, Salim; Gerstein, Hertzel C. // Diabetes Care;Mar2010, Vol. 33 Issue 3, p608 

    OBJECTIVE -- The objective of this study was to determine the degree to which ramipril and/or rosiglitazone changed β-cell function over time among individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) who participated in the Diabetes Reduction Assessment...

  • Prediabetes therapy and beta-cell function. Kuritzky, Louis // Primary Care Reports;May2010 Supplement, p9 

    The article discusses research being done on the impact of rosiglitazone and ramipril on beta-cell function in individuals suffering from impaired glucose tolerance or impaired fasting glucose, which references a study by A. J. Hanley and colleagues published in a 2010 issue of the journal...

  • Prediabetes therapy and beta-cell function. Kuritzky, Louis // Alternative Medicine Alert;May2010 Supplement, p9 

    The article discusses a study on the effect of prediabetes (PDM) therapy involving rosiglitazone and ramipril on beta-cell function in individuals with impaired glucose tolerance or impaired fasting glucose, results of which show that patients treated with rosiglitazone exhibited improvements.

  • Prediabetes therapy and beta-cell function. Kuritzky, Louis // Neurology Alert;May2010 Pharmacology, p9 

    The article discusses research done on the effect of rosiglitazone and ramipril on beta-cell function in people with impaired glucose tolerance or fasting glucose, referencing a study by A. J. Hanley et al, published in a 2010 issue of "Diabetes Care."

  • ACE Inhibitor Does Not Stop Progression to Diabetes. Trecroci, D. // Diabetes Health;Feb/Mar2007, Vol. 16 Issue 1, p27 

    The article highlights the result of a study on the effect of an angiotensin-converting-enzyme (ACE) inhibitor on persons with impaired fasting glucose levels or impaired glucose tolerance. Researchers found that the use of ramipril (Altace), an ACE inhibitor, for three years does not...

  • Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs). Mohamad, Hoda E.; Askar, Mervat E.; Hafez, Mohamed M. // Diabetology & Metabolic Syndrome;2011, Vol. 3 Issue 1, p1 

    Background: Diabetes mellitus (DM) and hypertension (HTN) are accused of being responsible for the development of the cardiac fibrosis due to severe cardiomyopathy. Methods: Blood glucose (BG) test was carried out, lipid concentrations, tumor necrosis factor alpha (TNF-α), transforming growth...

  • Effect of Diabetes Mellitus and Its Control on Myocardial Contractile Function in Rats. Alsawy, Bassem M.; El-Damarawi, Magdi A. // Macedonian Journal of Medical Sciences;Sep2014, Vol. 7 Issue 3, p431 

    AIM: This work was done to study the effect of both types of diabetes mellitus (DM) on myocardial contractility in rats. Also, we investigated the role of treatment of DM with insulin and rosiglitazone (used as treatment for type 1 and type 2 DM respectively) in improvement of myocardial...

  • Effects of rosiglitazone pretreatment on blood glucose, lipid levels, urea, and microalbuminuria in rats undergoing 70% pancreatectomy. Zafe Acar, Hasan; Okan Senel, Oytun; Bukan, Neslihan; Yurekli, Banu; Ebru Salman, A.; Yetisir, Fahri // Open Access Surgery;2013, Vol. 6, p1 

    Background: Partial pancreatectomy is one of the main causes of type II diabetes, which occurs because of insulin deficiency due to a decrease in the number of β-cells. Partial pancreatectomy is the treatment of choice particularly for pancreatic cysts, benign and malign tumors of the...

  • Are Diabetes Prevention Treatments Truly Disease Modifying? Kuritzky, Louis // Alternative Medicine Alert;Sep2011, p19 

    The article discusses the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Trial which showed that ramipril or rosiglitazone did not have a beneficial "legacy" effect in treating type 2 diabetes (DM2) since drug cessation led to a decline in beta-cell function.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics